Isotretinoin use and the risk of inflammatory bowel disease: A population-based cohort study

Journal of Investigative Dermatology

Volumn 133, Issue 4, 2013, Pages 907-912

  Alhusayen, Raed O ^a,b,c,d   Juurlink, David N ^a,b,c,d   Mamdani, Muhammad M ^b,c,e,f   Morrow, Richard L ^g   Shear, Neil H ^a,b,c,h   Dormuth, Colin R ^g  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ACNE; ADOLESCENT; ADULT; ARTICLE; CHILD; DISEASE ASSOCIATION; DISEASE COURSE; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

EID: 84875128114     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.387     Document Type: Article

References (28)

1. Bernstein CN, Nugent Z, Longobardi T et al. (2009) Isotretinoin is not associated with inflammatory bowel disease: a population-based casecontrol study. Am J Gastroenterol 104:2774-8
2. Brelsford M, Beute TC (2008) Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 27:197-206
3. Chen K, White TJ, Juzba M et al. (2002) Oral isotretinoin: an analysis of its utilization in a managed care organization. J Manag Care Pharm 8:272-7
4. Crockett SD, Porter CQ, Martin CF et al. (2010) Isotretinoin use and the risk of inflammatory bowel disease: a case-control study. Am J Gastroenterol 105:1986-93
5. Dubuquoy L, Dharancy S, Nutten S et al. (2002) Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 360:1410-8
6. Dubuquoy L, Rousseaux C, Thuru X et al. (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55:1341-9
7. Hanauer SB (2006) Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12(Suppl 1):S3-9
8. Hull PR, D'Arcy C (2003) Isotretinoin use and subsequent depression and suicide: presenting the evidence. Am J Clin Dermatol 4:493-505
9. Kahn MF, Chamot AM (1992) SAPHO syndrome. Rheum Dis Clin North Am 18:225-46
10. Kang SG, Lim HW, Andrisani OM et al. (2007) Vitamin A metabolites induce gut-homing FoxP3 regulatory T cells. J Immunol 179:3724-33
11. Layton AM, Knaggs H, Taylor J et al. (1993) Isotretinoin for acne vulgaris-10 years later: a safe and successful treatment. Br J Dermatol 129:292-6
12. Lindor NM, Arsenault TM, Solomon H et al. (1997) A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin Proc 72:611-5
13. Margolis DJ, Fanelli M, Hoffstad O et al. (2010) Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol 105:2610-6
14. Marks DJ, Harbord MW, MacAllister R et al. (2006) Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367:668-78
15. McAuley D, Miller RA (1985) Acne fulminans associated with inflammatory bowel disease. Report of a case. Arch Dermatol 121:91-3
16. Naranjo CA, Busto U, Sellers EM et al. (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-45
17. Norris DA, Osborn R, Robinson W et al. (1987) Isotretinoin produces significant inhibition of monocyte and neutrophil chemotaxis in vivo in patients with cystic acne. J Invest Dermatol 89:38-43
18. Reddy D, Siegel CA, Sands BE et al. (2006) Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol 101:1569-73
19. Reniers DE, Howard JM (2001) Isotretinoin-induced inflammatory bowel disease in an adolescent. Ann Pharmacother 35:1214-6
20. Shale M, Kaplan GG, Panaccione R et al. (2009) Isotretinoin and intestinal inflammation: what gastroenterologists need to know. Gut 58:737-41
21. Shalita AR, Cunningham WJ, Leyden JJ et al. (1983) Isotretinoin treatment of acne and related disorders: an update. J Am Acad Dermatol 9:629-38
22. Sundstrom A, Alfredsson L, Sjolin-Forsberg G et al. (2010) Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 341:c5812
23. van der Zee HH, van der Woude CJ, Florencia EF et al. (2010) Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 162:195-7
24. Voreacos D, Martin J (2010) Roche Ordered to Pay 25 Million to Accutane User (Update2). Bloomberg News. [http://www.bloomberg.com/apps/news?pid= newsarchive&sid=a7Oj2q25ZHZ8] 2010; Accessed 4 October 2012
25. Wakabayashi M, Fujimoto N, Uenishi T et al. (2011) A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory bowel disease. Dermatology 222:231-5
26. Williams JI, Young W (1996) A Summary of Studies on the Quality of Health Care Administrative Databases in Canada. In: Goel V, Williams JI, Anderson GM, Blackstein-Hirsch P, Fooks C, Naylor CD (eds) Patterns of Health Care in Ontario. 2nd ed. Canadian Medical Association: Ottawa, pp339-46
27. Zaba R, Schwartz R, Jarmuda S et al. (2011) Acne fulminans: explosive systemic form of acne. J Eur Acad Dermatol Venereol 25:501-7
28. Zouboulis CC (2006) Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. J Invest Dermatol 126:2154-6